Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3a Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Grade 1 Follicular Lymphoma
- Refractory Grade 2 Follicular Lymphoma
- Refractory Grade 3a Follicular Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma
Interventions
- PROCEDURE: Biopsy
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Marrow Aspiration
- PROCEDURE: Bone Marrow Biopsy
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- OTHER: Questionnaire Administration
- DRUG: Sonrotoclax
- DRUG: Zanubrutinib
Sponsor
City of Hope Medical Center
Collaborators